Ashok Leyland approves investments worth up to ₹850 crore in subsidiaries

Ashok Leyland’s board approved investments of up to ₹850 crore in Optare Plc and Hinduja Housing Finance. The company also reported its first quarter earnings on Friday.

Ashok Leyland’s board approved investments of up to ₹850 crore in Optare Plc and Hinduja Housing Finance. The company also reported its first quarter earnings on Friday.

Alkem Laboratories MD Sandeep Singh said the company had started FY27 on a steady note, with healthy growth across its India and international businesses. He said the India business continued to outperform the market, while growth in non-US international markets…

Bharat Dynamics posted a sharp improvement in its June-quarter performance, with profit rising more than six-fold and revenue more than doubling year-on-year, while the defence manufacturer swung to an EBITDA profit.

Natco Pharma shares fell sharply after weak Q1 earnings, with profit down 57% to Rs 206.5 crore. The board approved raising up to Rs 2,000 crore.

Hyderabad-based Nava reported a softer June quarter, with profit and operating earnings declining despite a modest rise in revenue. The energy business remained the company’s biggest revenue contributor, though its segment profit fell year-on-year.

As per the company’s management, its FY27 new hospital earnings before interest, taxes, depreciation and amortization (EBITDA) loss is guided at ₹140 crore to ₹150 crore and is unchanged from its March quarter call.

Transformers & Rectifiers India has received a Letter of Intent worth ₹100-500 crore from APTRANSCO for manufacturing transformers and related works, with delivery scheduled over the next 13 months.

Apex Frozen Foods reported a net profit of ₹22 crore for the June 2026 quarter, compared with ₹9 crore in the corresponding quarter a year earlier. Revenue remained largely flat at ₹257 crore, compared with ₹258 crore in the year-ago…

Abizer Diwanji, Founder of NeoStrat Advisors sees the deal bringing fresh capital, global visibility and access to overseas funding for Jio Credit, while intensifying competition in digital lending.

Carlyle was looking at selling 6% of its for ₹1,750 crore in Piramal Pharma via a block deal. CNBC-TV18 had reported regarding the same on Thursday. However, sources on Friday said the block deal had been cancelled.